US9475795, 3

ID: ALA3981081

PubChem CID: 72548855

Max Phase: Preclinical

Molecular Formula: C18H22F3N3O4S

Molecular Weight: 433.45

Molecule Type: Small molecule

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  Cc1nn(C)c(C)c1S(=O)(=O)N1CCC(Oc2ccc(OC(F)(F)F)cc2)CC1

Standard InChI:  InChI=1S/C18H22F3N3O4S/c1-12-17(13(2)23(3)22-12)29(25,26)24-10-8-15(9-11-24)27-14-4-6-16(7-5-14)28-18(19,20)21/h4-7,15H,8-11H2,1-3H3

Standard InChI Key:  HRJWLVQPOCRWBC-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 29 31  0  0  0  0  0  0  0  0999 V2000
    3.1417    1.5281    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.0377    0.7299    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5052    1.0408    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.2543   -0.2587    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.4477   -0.3849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2499   -1.3728    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4917   -2.5482    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8990   -0.7508    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5988   -1.5004    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    2.5984   -2.7004    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.6377   -2.1009    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.2990   -0.7500    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.2990    0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    1.5000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2990    0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2990   -0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000   -1.5000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6003    1.4977    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8990    0.7455    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -5.2007    1.4909    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4972    0.7364    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -6.4920   -0.7636    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7876   -1.5212    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7802   -3.0220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -8.8161   -3.6277    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -6.7379   -3.6166    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -7.7738   -4.2220    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -5.1903   -1.5091    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8939   -0.7546    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  1  0
  4  6  1  0
  6  7  1  0
  6  8  2  0
  8  2  1  0
  8  9  1  0
  9 10  2  0
  9 11  2  0
  9 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 12  1  0
 15 18  1  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 24 26  1  0
 24 27  1  0
 22 28  1  0
 28 29  2  0
 29 19  1  0
M  END

Associated Targets(Human)

PROKR1 Tchem Prokineticin receptor 1 (175 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 433.45Molecular Weight (Monoisotopic): 433.1283AlogP: 3.17#Rotatable Bonds: 5
Polar Surface Area: 73.66Molecular Species: NEUTRALHBA: 6HBD:
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 2.16CX LogP: 2.87CX LogD: 2.87
Aromatic Rings: 2Heavy Atoms: 29QED Weighted: 0.72Np Likeness Score: -1.64

References

1.  (2016)  Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases, 

Source

Source(1):